Investigation of Plasma Proteins in Patients With Hereditary Haemorrhagic Telangiectasia and PAVMs

Studies of Plasma Proteins Derived From Pulmonary Arteriovenous Malformation Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00230672

Enrollment

Registered

2005-10-03

Start date

2005-03-31

Completion date

2008-03-31

Last updated

2023-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Telangiectasia, Hereditary Hemorrhagic

Keywords

Hereditary Hemorrhagic

Brief summary

Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an disease that leads to the development of dilated and fragile blood vessels, including arteriovenous malformations in the lungs (PAVMs). We hypothesize that the genetically-determined abnormality in the blood vessels of HHT patients leads to alteration in the concentrations or activity of several proteins in the blood stream. We propose to take blood samples from patients at defined times in order to study changes in blood protein levels and activity

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

Patients with hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations -

Exclusion criteria

Unable to provide informed consent \-

Countries

United Kingdom

Outcome results